A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy
Latest Information Update: 01 Mar 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Rotator cuff injuries
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 24 Feb 2025 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: Project discontinued to prioritize other key programs in portfolio)
- 12 Jul 2024 Planned End Date changed from 16 Dec 2024 to 13 Dec 2024.
- 12 Jul 2024 Planned primary completion date changed from 21 Oct 2024 to 18 Oct 2024.